PD-1 Antibody and Lenvatinib Plus TACE on Downstaging BCLC B/C HCC
The purpose of this study is to assess the difference of safety and efficacy about PD-1 Antibody and Lenvatinib Plus transcatheter arterial chemoembolization (TACE) on downstaging hepatocellular carcinoma with BCLC B/C.
Hepatocellular Carcinoma
COMBINATION_PRODUCT: PD-1 and Lenvatinib Plus TACE
Resection rate, Resction rate refers to the proportion of patients who can receive radical surgery after downstaging treatment., 6 months after downstaging treatment
Adverse events (safety), Postoperative adverse events (safety ) will be evaluated according to the NCI CTCAE Version 4.03.The number and severity of treatment-related side effects, including AE and SAE, will be recorded during treatment., 6 months|Overall survival (OS), The duration from the date of recruitment to the date of death from any cause., 2 years|Objective response rate (ORR), ORR is defined as the percentage of participants who have a confirmed complete response or partial response according to RECIST 1.1 or mRECIST., 6 months|Progression free survival (PFS), PFS is defined as the time from enrollment of the trial to the first documented disease progression or death due to any cause., 6 months
The purpose of this study is to assess the difference of safety and efficacy about PD-1 Antibody and Lenvatinib Plus transcatheter arterial chemoembolization (TACE) on downstaging hepatocellular carcinoma with BCLC B/C.